Pricing Log in Create free account

Pharming Group N.V. Sponsored ADR (PHAR) vs Rigel Pharmaceuticals, Inc. (RIGL)

Pharming Group N.V. Sponsored ADR and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Pharming Group N.V. Sponsored ADR and Rigel Pharmaceuticals, Inc. are of similar size ($870.6M and $853.9M). Rigel Pharmaceuticals, Inc. trades at the lower P/E: 2.4× against 34.2×. Pharming Group N.V. Sponsored ADR grew revenue faster over the last twelve months: 6.76% against 2.18%. Rigel Pharmaceuticals, Inc. has the higher net margin (106.6% vs 6.27%) and the higher return on invested capital (13.7% vs 10.1%). Across the 22 metrics below, Rigel Pharmaceuticals, Inc. leads on 15 and Pharming Group N.V. Sponsored ADR on 7.

Valuation

Metric PHAR RIGL Biotechnology median
P/E 34.22 2.35 10.60
P/S 2.23 2.57 9.40
P/B 2.96 1.66 2.13
Price to free cash flow 25.00 37.96 25.18
EV/EBITDA 17.39 8.30 0.66
EV/Sales 2.00 2.28 9.02
Earnings yield 2.92% 42.49% (32.88%)
Free cash flow yield 4.00% 2.63% (23.13%)

Profitability

Metric PHAR RIGL Biotechnology median
Gross margin 85.10% 89.64% 68.51%
Operating margin 8.40% 26.28% 0.00%
Net margin 6.27% 106.59% 0.00%
Free cash flow margin 8.92% 31.20% 0.00%
Return on equity 8.73% 109.18% (51.96%)
Return on assets 5.00% 80.16% (46.06%)
Return on invested capital 10.07% 13.69% 0.00%

Growth

Metric PHAR RIGL Biotechnology median
Revenue growth (TTM) 6.76% 2.18% 6.76%
EPS growth (last fiscal year) 125.00% 1,867.68% 29.88%
Revenue growth, 5-year CAGR 12.13% 22.06% 9.75%
Net income growth, 5-year CAGR (40.35%) 0.00% 0.00%

Health

Metric PHAR RIGL Biotechnology median
Debt to equity 0.34 0.00 0.00
Current ratio 3.23 2.39 4.97
Net debt to EBITDA (2.21) (1.05) 1.01

Dividend

Metric PHAR RIGL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PHAR RIGL Biotechnology median
Market cap 870.59m 853.86m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack